

March 21, 2014



BioCorRx, Inc. Announces Three New Additions to Advisory Board

Los Angeles, March 21, 2014 (GLOBE NEWSWIRE) --[BioCorRx, Inc.](#) (OTCQB: BICX), a leader in addiction treatment and rehabilitation programs, announces three new additions to its advisory board. The new advisors will provide informed guidance to the company's directors and management.

Dr. Gil Price, CEO of Drug Safety Solutions, is a clinical physician trained in Internal Medicine with an emphasis on adverse drug reactions, drug utilization, therapeutic drug development and regulation. With over 26 years of experience in his field, Dr. Price has served as Director of Clinical Development for Oncology at MedImmune Inc., and held research positions with Glaxo, Inc. and ClinTrials. Dr. Price is a member of the American Medical Association, the Academy of Pharmaceutical Physicians, the American Society of Microbiology, the Association of Clinical Research Professionals, and the Drug Information Association.

Mark Sorrentino, MD, MS, is an expert in drug development who currently serves as Executive Medical Director, Global Product Development at Pharmaceutical Product Development, LLC. Dr. Sorrentino has previously served as global Chief Medical Officer at ADMA Biologics, Director of Medical Science at MedImmune, and consultant for multiple biotechnology firms. Dr. Sorrentino has extensive experience in the development and oversight of numerous clinical trials as well as Phase IV and post-marketing studies across several therapeutic areas. Dr. Sorrentino received his MD and MS from the Chicago Medical School, and completed both a residency in Pediatrics and fellowship in Pediatric Critical Care at Children's National Medical Center in Washington, D.C., where he served as an attending physician in the pediatric intensive care unit for 8 years. Dr. Sorrentino holds active medical licenses in Washington, D.C. and Maryland, is on the Board of Directors of the CMR Institute, and holds an appointment as Assistant Clinical Professor at the George Washington University School of Medicine.

Richard Haatvedt holds a BSBA in accounting from Portland State University and is currently part owner and Chief Financial Officer of Dakavia Management Corp., a healthcare company in the Northwestern United States. Richard has held key financial positions at several large companies including Lindsay Enterprises, Inc., and was instrumental in setting up TAK Management, LLC, a California medical billing company that handles millions of dollars' worth of insurance billing services. Richard regularly prepares financial statements and general ledger analysis for several companies and has extensive experience in accounting, business planning, budgeting, human resources as well as the creation of policies and procedures.

"We are pleased that these three additions to our advisory board have such a breadth of experience that can benefit the company. Both Drs. Price and Sorrentino have invaluable experience consulting with companies on FDA matters, which is extremely beneficial to

BioCorRx down the line" stated CEO Kent Emry.

Recent Media

<https://vimeo.com/88412943>

<http://ehealthradio.podbean.com/2014/02/22/biocorr-inc-the-treatment-of-alcoholism-with-its-revolutionary-start-fresh-program/>

<http://thestockradio.com/ceyyfresh-start-private-management-inc-coo-brady-granier/>

<https://vimeo.com/85537808>

<https://vimeo.com/84401532>

<http://vimeo.com/m/84960767>

<http://www.thedoctorstv.com/video/lib/init/10691>

About BioCorRx

BioCorRx, Inc. (OTCQB: BICX) is an addiction treatment and rehabilitation company on the leading edge of substance abuse addiction treatment. The company has developed a highly effective program called the Start Fresh ProgramTM consisting of two components used by various addiction clinics in the US. Clinic reports show that the treatment program has an 85% success rate with individuals that complete the program. The first component of the program consists of an outpatient implant procedure performed by a licensed physician that delivers therapeutic levels of the drug Naltrexone, an opioid antagonist that significantly reduces physical cravings for alcohol and opioids, into the body. The second component of the program developed by BioCorRx is a one on one coaching program specifically tailored for the treatment of alcoholism and other substance abuse addictions. For more information on BICX, visit www.BioCorRx.com

Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

CONTACT: Investor Relations

Maximum Performance Advisors, Inc.

858-381-4677

Source: BioCorRx